Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.67 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.67 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KIF11 | P52732 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26556365 | 0.88 | CYP11B2 (0.63) | CYP2A6MKNK1MKNK2CYP3A4ALDH1A1 | |
| SCHEMBL26553137 | 0.88 | CYP11B2 (0.63) | CYP2A6MKNK1MKNK2CYP3A4ALDH1A1 | |
| SCHEMBL16068455 | 0.85 | CYP2A6 (0.62) | CYP2A6MKNK1MKNK2CYP3A4ALDH1A1 | |
| SCHEMBL10035328 | 0.83 | MKNK1 (0.53) | CYP2A6MKNK1MKNK2CYP3A4CYP19A1 | |
| SCHEMBL24534338 | 0.82 | CYP2A6 (0.88) | CYP2A6MKNK1MKNK2CYP3A4ALDH1A1 | |
| SCHEMBL29360677 | 0.82 | CYP2A6 (0.88) | CYP2A6MKNK1MKNK2CYP3A4ALDH1A1 | |
| SCHEMBL13907273 | 0.82 | CYP2A6 (0.88) | CYP2A6MKNK1MKNK2CYP3A4ALDH1A1 | |
| SCHEMBL21442882 | 0.82 | CYP2A6 (0.58) | CYP2A6MKNK1MKNK2CYP3A4ALDH1A1 | |
| SCHEMBL12435674 | 0.82 | CYP3A4 (0.64) | CYP2A6MKNK1MKNK2CYP3A4ALDH1A1 | |
| Bromide SCHEMBL29018737 | 0.82 | ALDH1A1 (0.58) | CYP2A6MKNK1MKNK2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663204-B1 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2014-05-07 | — | — | EP | claimed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| WO-2023158221-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | 주식회사 카나프테라퓨틱스 | 2023-08-24 | — | — | WO | disclosed |
| US-11718583-B2 | Nitrogen-containing compound, electronic component using same and electronic device | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| EP-3377221-B1 | A METHOD OF CROSS-COUPLING USING A TRANSITION METAL COMPLEX COMPRISING A PAD3 LIGAND | UNIV PRINCETON (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| EP-3242875-B1 | 4,5-DIHYDROIMIDAZOLE DERIVATIVES AND THEIR USE AS HISTONE DEMETHYLASE (KDM2B) INHIBITORS | GENENTECH INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053193-A2 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053725-A2 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
| US-20050148623-A1 | Prevent reproduct of aids virus | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | CTPS1, CTPS2, TBXAS1 | CYP2A6 3540/4885MKNK1 2421/4885MKNK2 2359/4885 |
| US-20050148623-A1 | Prevent reproduct of aids virus | SERPINB1, PRSS1, SERPINA3 | CYP2A6 580/4885MKNK1 2713/4885MKNK2 3218/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | CYP2A6 1651/4885MKNK1 311/4885MKNK2 481/4885 |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | CYP2A6 4390/4885MKNK1 518/4885MKNK2 597/4885 |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | CYP2A6 3496/4885MKNK1 67/4885MKNK2 45/4885 |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | PTGER1, PTGIR, PTGDR2 | CYP2A6 457/4885MKNK1 3446/4885MKNK2 2859/4885 |
| US-11718583-B2 | Nitrogen-containing compound, electronic component using same and electronic device | EXOC1, NOS1, EXOSC10 | CYP2A6 4002/4885MKNK1 3809/4885MKNK2 3754/4885 |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | GABRA5, GABRA3, GABRA6 | CYP2A6 49/4885MKNK1 4135/4885MKNK2 3685/4885 |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | BAD, GABRA5, GABRB1 | CYP2A6 1415/4885MKNK1 1554/4885MKNK2 1518/4885 |
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | MRPS23, RPP30, RPS19 | CYP2A6 3670/4885MKNK1 1761/4885MKNK2 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.